Toronto, Ontario - TheNewswire - October 23, 2023 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT) (OTC:VPTDF) will hold its annual general and special meeting of Shareholders (the “AGM”) on Wednesday, November 1, 2023 at 11:00 a.m. EST in a virtual-only format conducted via gotomeeting for the following purposes:

1. To receive the audited financial statements of the Corporation;  

2. To appoint auditors for the Corporation; 

3. To elect each of the directors of the Corporation; and 

4. To re-approve and ratify the Corporation’s incentive stock option plan. 

Following the AGM, President and CEO, Dr. Alvira Macanovic, will provide a corporate update.

Call in details for the virtual-only AGM are as follows:

In order to dial into the Meeting within Canada, shareholders and observers will phone +1 (647) 497-9391 and enter the Access Code noted below.

Outside of Canada, please find your local number:

United States: +1 (646) 749-3129

France: +33 430 001 234

Germany: +49 721 9881 4161

Ireland: +353 16 572 651

Netherlands: +31 207 941 377 Spain: +34 912 71 8491

Sweden: +46 853 527 836

Switzerland: +41 435 5015 61

United Kingdom: +44 330 221 0088

Access Code for Dial In: 923-830-821

Shareholders and observers may also join the Meeting by computer, tablet or smartphone by downloading the application at https://meet.goto.com/install and, once the application is loaded, opening the following link for the meeting: https://meet.goto.com/92383082.

The notice and management information circular and form of proxy for the AGM are available on the Corporation’s website at https://www.ventripoint.com/annual-meeting and under the Corporations profile at www.sedarplus.ca. The Board has fixed September 25, 2023 as the record date (the "Record Date") for determining the shareholders entitled to receive notice of the annual general meeting or any adjournment or postponement thereof. Holders of record of the Company's ordinary shares at the close of business on the Record Date are entitled to attend the annual general meeting and any adjournment or postponement thereof in person.

Ventripoint’s financial information is available on the Corporation’s website at  https://www.ventripoint.com/financial.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Jonathan Robinson

This email address is being protected from spambots. You need JavaScript enabled to view it.

416-669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.